Evofem Biosciences, Inc. (EVFM)
| Previous Close | 0.2040 |
| Open | 0.2200 |
| Bid | 0.0000 x 1100 |
| Ask | 0.0000 x 1800 |
| Day's Range | 0.1875 - 0.2290 |
| 52 Week Range | 0.1600 - 12.3000 |
| Volume | |
| Avg. Volume | 33,303,706 |
| Market Cap | 16.316M |
| Beta (5Y Monthly) | -1.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -19.0060 |
| Earnings Date | Nov 14, 2022 - Nov 18, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.01 |
- ACCESSWIRE
Traders News Source Senior Editor, Mark Roberts Interviews Evofem Biosciences, Inc. CEO Saundra Pelletier
Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Evofem Biosciences.
- Newsfile
Evofem Biosciences Discusses Innovative Woman-Controlled Contraceptive with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - August 1, 2022) - The Stock Day Podcast welcomed Evofem Biosciences (NASDAQ: EVFM) ("the Company"), an innovator in women's sexual and reproductive health and the maker of hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate). Evofem's CEO, Saundra Pelletier, joined Stock Day host Sever Copley. "What is Phexxi and how does it fit into the contraceptive landscape?" asked Copley. "Phexxi is the first and only birth control produc
- Yahoo Finance Video
Short interests in Evofem jumps from 6% to 50% in June following the Roe v. Wade decision
Yahoo Finance's Alexandra Semenova joins the Live show to detail the surge in short interests for birth control developer Evofem Biosciences, as U.S. companies continue to remain silent on abortion following the Roe v. Wade decision.
